胰腺癌相关基因研究进展

汤永辉; 高乃荣; 石欣

胰腺癌相关基因研究进展

基金项目:

江苏省卫生科研项目基金资助(项目号WK200238)；国家自然科学基金资助(项目号30500491)；

详细信息

中图分类号: R735.9
计量
- 文章访问数: 3374
- HTML全文浏览量: 6
- PDF下载量: 1150
- 被引次数: 0
出版历程
- 出版日期: 2006-03-20

Research funding:

摘要

HTML全文

参考文献(20)

[1] G reen lee RT, H ill-Harmon MB, Murray T, et al.Cancer Statis-tics, 2001[J].Cancer J C lin, 2001, 51 (1) ∶15-36.

[2] Kelly JR, Fraser MM, Hubbard JM, et al. CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer[J].Anticancer Res, 2003, 23 (3) ∶2007-2013.

[3] Ish iiH, Dumon KR, Vecch ione A, et al.E ffect of adenoviral-tra-bsduction of the fragile h istid ine triad gene into esophageal cancercell[J].Cancer Res, 2001, 61 (4) ∶1578-1584.

[4] Sorio C, Baron A, Orlandini S, et al. The FHIT gene in expressed in pancreatic ductular cell and is altered in pancreatic cancer[J].Cancer Res, 1999, 59 (6) ∶1308-1314.

[5] Yu Y, Fujii S, Yuan J, et al. Epigenetic regulation of ARHI in breast and ovarian cancer cells[J].Ann N Y Acad Sci, 2003, 983∶268-277.

[6] Kaiuman P, Gozani O, Odze RD, et al. The Pentz-Jedges gene product LKBlis a mediator of p53-dependent cell death[J].Mol Cell, 2001, 7 (6) ∶1307-1319.

[7] Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Pentz-Jedges gene inactivation in antraductal papillary-mucinous neoplasms of the oancreas[J].Am J Pathol, 2001, 159 (6) ∶2017-2022.

[8] Su GH, Banal R, Murphy KM, et al.ACVR1B (ALK4, a active re-ceptor type1β) gene mutation in pancreatic carcinoma[J].PNAS, 2001, 98 (6) ∶3254-3257.

[9] Wada M, Yazumi S, Takaishi S, et al. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines[J].Oncogene, 2004, 23 (13) ∶2401-2407.

[10] Li QL, Ito K, Sakakura C, et al. Casual relationship between the loss of RUNX3 expression and gastic cancer[J].Cell, 2002, 109 (1) ∶113-124.

[11] Balmain A. Cancer: new-age tumor suppressors[J].Nature, 2002, 417 (6886) ∶235-237.

[12] Rosty C, Uek i T, Argan i P, et al.Ovexespression of S100A4 inpancreatic ductal adeocarcinomas is associated w ith poor d ifferentia-tion and DNA hypom ethylation[J].Am J Pathol, 2002, 160 (1) ∶45-50.

[13] Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpression in pancreatic adenocarcinoma[J].Cancer Res, 2001, 61 (11) ∶4320-4321.

[14] Burbee DG, Forgacs E, Zochnauer-muller S, et al. Epigenetic anactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression[J].J Natl Cancer Inst. 2001, 93 (9) ∶691-9.

[15] House MG, Herman JG, Cuo MZ, et al.Abberant hyperm ethyla-tion of tumor suppressor genes in pancreatic endocrine neoplasm s[J].Ann Surg, 2003, 238 (3) ∶423-431.

[16] Khokhlatchev A, Rabizadeh S, Xavier R, et al. Identification of a novel RAS-regulated proapoptotic pathway[J].Curr Biol, 2002, 12 (2) ∶253-265.

[17] Sh ivakumar L, M inna J, sakamak i T, et al.The RASSF1A tumorsuppressor b locks cell cycle progression and inh ib its cyclin D1 accu-mu lation[J].Mol Cell B iol, 2002, 22 (12) ∶4309-4318.

[18] Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer[J].Nature, 2002, 417 (6892) ∶949-954.

[19] Ishimura N, Yamasawa K, Karim Rumi MA, et al. BRAF and K-ras gene mutations in human pancreatic cancers[J].Cancer Lett, 2003, 199 (2) ∶169-173.

[20] Calhoun ES, Jones JB, Ashfaq R, et al.BRAF and FBXW 7 (CDC4, FBW 7, AGO, SEL10) mutations in d istinct subsets of pan-creatic cancer:potential therapeutic targets[J].Am J Pathol, 2003, 163 (4) ∶1255-1260.

施引文献

资源附件(0)

访问统计